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Abstract
Background: Tuberous sclerosis complex (TSC) is a multisystem disease with prominent neurologic manifestations
such as epilepsy, cognitive impairment and autism spectrum disorder. mTOR inhibitors have successfully been used
to treat TSC-related manifestations in older children and adults. However, data on their safety and efficacy in infants
and young children are scarce. The objective of this study is to assess the utility and safety of mTOR inhibitor
treatment in TSC patients under the age of 2 years.
Results: A total of 17 children (median age at study inclusion 2.4 years, range 0–6; 12 males, 5 females) with TSC who
received early mTOR inhibitor therapy were studied. mTOR inhibitor treatment was started at a median age of 5
months (range 0–19months). Reasons for initiation of treatment were cardiac rhabdomyomas (6 cases), subependymal
giant cell astrocytomas (SEGA, 5 cases), combination of cardiac rhabdomyomas and SEGA (1 case), refractory epilepsy
(4 cases) and disabling congenital focal lymphedema (1 case). In all cases everolimus was used. Everolimus therapy was
overall well tolerated. Adverse events were classified according to the Common Terminology Criteria of Adverse Events
(CTCAE, Version 5.0). Grade 1–2 adverse events occurred in 12 patients and included mild transient stomatitis (2 cases),
worsening of infantile acne (1 case), increases of serum cholesterol and triglycerides (4 cases), changes in serum
phosphate levels (2 cases), increase of cholinesterase (2 cases), transient neutropenia (2 cases), transient anemia (1 case)
, transient lymphopenia (1 case) and recurrent infections (7 cases). No grade 3–4 adverse events were reported.
Treatment is currently continued in 13/17 patients. Benefits were reported in 14/17 patients and included decrease of
cardiac rhabdomyoma size and improvement of arrhythmia, decrease of SEGA size, reduction of seizure frequency and
regression of congenital focal lymphedema. Despite everolimus therapy, two patients treated for intractable epilepsy
are still experiencing seizures and another one treated for SEGA showed no volume reduction.
Conclusion: This retrospective multicenter study demonstrates that mTOR inhibitor treatment with everolimus
is safe in TSC patients under the age of 2 years and shows beneficial effects on cardiac manifestations, SEGA
size and early epilepsy.
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Background
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant neurodevelopmental disorder caused by loss-of-f-
unction mutations in the TSC1 and TSC2 genes,
encoding the Tuberin-Hamartin complex, acting as a
critical upstream suppressor of the mammalian target of
rapamycin (mTOR), a key signaling pathway controlling
cellular growth and metabolism. TSC is a multisystem
disease, and about 90% of individuals develop central
nervous system complications, such as epilepsy, cogni-
tive impairment and autism spectrum disorder [1, 2].
Epilepsy, usually starting during the first 3 years of life,
occurs in 83.5% of affected patients and represents the
most prevalent and challenging clinical manifestation of
TSC [2, 3]. Early-onset epilepsy typically presents with
focal seizures with or without secondary generalization
often evolving into infantile spasms (IS) during infancy.
IS or West syndrome, a severe epileptic encephalopathy
characterized by epileptic spasms and a pathognomonic
EEG pattern (hypsarrhythmia), occurs in 38.8% of TSC
patients [3]. Antiepileptic treatment with vigabatrin or
adrenocortictropic hormone (ACTH) has proven to stop
IS in 71.5% of TSC patients [3].
mTOR inhibition is a promising molecular target for
the treatment of TSC manifestations, including epilepsy
and behavior. The mTOR inhibitors rapamycin (siroli-
mus) and everolimus have been increasingly used in
TSC. Everolimus has gained approval for the treatment
of TSC-related subependymal giant cell astrocytomas
(SEGA) and renal angiomyolipomas. In a phase I/II clin-
ical trial including 20 children with TSC-related refrac-
tory epilepsy above the age of 2 years, everolimus led to
a median seizure reduction of 73% with only mild to
moderate adverse effects [4]. Recently, the EXIST-3 trial
showed a significant seizure reduction in a large cohort
of TSC patients aged 2–65 years treated with everolimus
[5] and led to the additional approval for the treatment
of refractory focal seizures in TSC above 2 years of age.
TSC-related early-onset epilepsy in the first year of life
and in particular infantile spasms (IS) are the most im-
portant risk factors for mental impairment and autism
spectrum disorder. In TSC, 74.4% of patients with IS
develop cognitive impairment, while only 39.2% of pa-
tients without IS show neurologic deficits [6, 7]. It can
be hypothesized that early initiation of mTOR inhibitor
treatment reduces the risk for TSC-related neuropsychi-
atric deficits [8–10]. However, data on safety and efficacy
of everolimus treatment in infants and young children
are still lacking and only one study analyzed clinical data
of TSC patients treated with everolimus within the first
2 years of life [11].
The main purpose of this study is to collect data on
the tolerability of mTOR inhibitors and the occurrence
of adverse events in neonates and infants under 2 years
of age. We further aimed at collecting preliminary data on
the effects of mTOR inhibitor treatment on TSC-related
malformations, epilepsy and neurodevelopment.
Results
Cohort
We collected data from 17 patients with a definite (clinical
and/or genetic) diagnosis of TSC according to the 2012
International TSC Consensus Conference [12] (for clinical
data see Table 1). Twelve patients were male, 5 female.
Median age at inclusion into this study was 2.4 years
(range 0–6 years). The median period of follow-up was
2.1 years (range 0.5–5.5 years). Diagnosis of TSC was sus-
pected prenatally due to cardiac rhabdomyomas in 14
cases and due to a SEGA in 1 case (patient #12). Two
patients initially presented with focal seizures and neuro-
imaging was suggestive of TSC (patients #1 and #16). In
addition, we collected follow-up data in one case (patient
#14) that has been published previously [13].
Genetic analysis was carried out in 12 of the 17 cases.
One child carried a mutation in TSC1 and 10 patients in
TSC2. No mutation could be identified in patient #17.
No genetic information was available in the remaining 5
cases. TSC occurred sporadically in 15 patients while
family history was positive in 2 patients.
Three patients were born pre-term due to cardiac
complications (patients #9, #11 and #13). All other pa-
tients were born at term with a normal birth weight and
normal APGAR scores. Dermatologic manifestations
were present in 11 cases, including white spots, facial
angiofibromas, periungual fibromas, and a shagreen
patch. Retinal hamartomas were present in 3 individuals.
Two patients developed renal angiomyolipomas.
Another patient showed an atypical manifestation with
hemihypertrophy, congenital focal lymphedema of the
leg, lumbar scoliosis and vascular anomalies including
aneurysms and renal artery stenosis. Overall 14/17 pa-
tients (82.4%) suffered from epileptic seizures. Seizure
types included focal, generalized and atonic seizures, and
in one case infection-related status epilepticus with
Todd’s palsy. IS developed in 7 cases (41.2%) with a me-
dian age at onset of 5.5 months (range 1-7 months).
Neuroimaging revealed tubers in 14/17 patients (82.4%),
subependymal nodules (SEN) in 12 (70.6%), and SEGA
in 7 patients (41.2%). Neuroimaging was normal in 2
cases (11.8%). Initial neuropsychological assessment was
normal in 5 of 14 tested children (35.7%). Nine patients
(64.3%) showed various degrees of developmental delay.
In 3 cases, no data concerning neurologic development
were available.
Reasons for initiation of mTOR inhibitor treatment
were symptomatic cardiac rhabdomyomas and arrhythmia
in 6 (35.3%), SEGA in 5 (29.4%), the combination of
cardiac rhabdomyoma and SEGA in 1 (5.9%), refractory
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epilepsy in 4 cases (23.5%) and congenital focal lymph-
edema in 1 case (5.9%) (Table 1, Fig. 1).
In all subjects everolimus (Certican™, Votubia™) was
used as mTOR inhibitor. Everolimus was administered
orally in all cases. Therapy was conducted with a median
age at initiation of 5 months (range 0–19months).
Safety profile of everolimus therapy
Data on the safety profile of everolimus therapy are
summarized in Table 2. Dosing regimens and absolute
dosages varied significantly between centers. In gen-
eral, newborns up to 3 months received everolimus in
doses ranging from 0.05–0.3 mg daily, while infants
older than 5 months received higher doses ranging
from 1 to 5 mg daily.
Adverse events were classified according to the Com-
mon Terminology Criteria of Adverse Events (CTCAE,
Version 5.0 [14]). Grade 1–2 adverse events occurred in
12 cases with a median of 1 adverse event (range 0–5)
per individual and included mild transient stomatitis (2
Table 1 Clinical data
Patient
#
Sex Age at
inclusion [y]
Age at
Diagnosis [d]
Mutation sporadic /
familial
First clinical
manifestation
Reason for mTOR
inhibition
Further manifestations
1 f 4.3 210 TSC2 sporadic Epilepsy SEGA Neuro: tubers, SEN, migration
lines, DD
2 m 6.2 prenatal TSC2 sporadic CR Congenital focal
lymphedema
Skin: subungual fibromas
Neuro: Epilepsy, tubers, SEN, DD
Other: lumbar scoliosis, aneurysms,
renal artery stenosis
3 f 0 prenatal NA familial CR SEGA Skin: angiofibromas, white spots,
Shagreen patch
Neuro: Epilepsy, tubers, DD
4 m 0.1 49 NA sporadic CR SEGA Skin: angiofibromas, white spots
Neuro: Epilepsy, tubers, DD
5 m 1.5 60 NA sporadic CR Epilepsy Skin: white spots
Neuro: tubers, SEN, DD
Other: retinal hamartomas
6 m 0 prenatal TSC2 familial CR CR None
7 f 3.1 prenatal TSC2 sporadic CR CR Skin: white spots
Neuro: Epilepsy, tubers, SEN, DD
8 f 5.1 prenatal NA sporadic CR SEGA Skin: white spots
Neuro: Epilepsy, tubers, SEN, white
matter lesions, DD
Other: retinal hamartomas
9 m 4 prenatal TSC2 sporadic CR CR / SEGA Skin: white spots
Neuro: Epilepsy, tubers, SEN,
migration lines, DD
10 m 4.1 30 NA sporadic CR Epilepsy Skin: white spots
Neuro: tubers, SEGA, aberrant
gyrification
Other: renal angiomyolipoma
11 f 1.7 30 TSC2 sporadic CR CR Neuro: Epilepsy, tubers, SEN, DD
12 m 2.1 0 TSC2 sporadic SEGA SEGA Neuro: Epilepsy, tubers, SEN, white
matter lesions, DD
Cardiac: CR
13 m 2.6 15 TSC2 sporadic CR CR Skin: white spots
Neuro: tubers, SEN, DD
14 m 3.3 prenatal TSC 2 sporadic CR CR Skin: white spots, angiofibromas
Neuro: Epilepsy, SEN, DD
15 m 0.9 prenatal TSC1 sporadic CR CR None
16 m 0.3 90 TSC2 sporadic Epilepsy Epilepsy Neuro: tubers, SEN, DD
Cardiac: CR
Other: retinal hamartomas, renal
angiomyolipoma
17 m 2.4 30 None sporadic CR Epilepsy Skin: white spots
Neuro: tubers, SEN, DD
CR cardiac rhabdomyoma, DD developmental delay, NA not available, SEGA subependymal giant cell astrocytoma, SEN subependymal nodule
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cases), worsening of infantile acne (1 case), increase of
serum cholesterol and triglycerides (4 cases), changes in
serum phosphate levels (2 cases), increase of cholinester-
ase (2 cases), increase of serum lactate dehydrogenase (1
case), transient neutropenia (2 cases), transient anemia
(1 case), transient lymphopenia (1 case) and recurrent
infections (7 cases) (Fig. 2). No grade 3–4 adverse events
were reported. Treatment is currently ongoing in 13 of
17 patients. Everolimus treatment was discontinued due
to rapid shrinkage of a cardiac rhabdomyoma after 19
days of treatment without rebound tumor growth within
a 5 month follow-up period in patient #14 [13], because
of stable disease after significant reduction of a SEGA in
patient #12, presurgically before removal of an epilepto-
genic tuber in patient #16, and due to lack of improve-
ment of seizures in patient #17.
Comedications during everolimus therapy included
vigabatrin, valproate, levetiracetam, oxcarbazepine, topir-
amate, lamotrigine, sultiame, phenobarbital, ACTH,
propranolol, flecainide, metoprolol, amiodarone, metildi-
goxin, propafenone, sotalol, trimethoprim, ketogenic diet
and modified Atkins diet. In one girl (patient #7) a
decrease in trough levels of oxcarbazepine was observed
after initiation of everolimus. No other relevant interac-
tions with everolimus treatment were reported.
Routine check-ups were performed in 2 monthly to
yearly intervals and included routine laboratory
work-up with complete blood count, liver and kidney
studies, serum triglycerides and cholesterol as well as
drug trough levels, EEG studies and cardiac and
neurologic imaging.
Vaccination status and social integration of children
before and during everolimus therapy were assessed
where data were available (Table 2). In 5/17 children
vaccination status was completed in accordance to offi-
cial recommendations before initiation of everolimus
treatment. During treatment live vaccines were avoided
in 6 patients. In one child vaccinations were performed
during a treatment pause of 3 months (patient #10). In
two patients, who were treated with everolimus in the
neonatal period, vaccinations including live vaccines
were conducted according to official recommendations
despite everolimus treatment (patient #9 and #11). No
vaccination related adverse events were reported.
Changes of cardiac manifestations and SEGA size under
everolimus therapy
Sixteen of 17 patients (94.1%) showed cardiac rhabdo-
myomas at birth. In 7 of these 16 cases (43.8%) everoli-
mus was initiated due to obstruction of cardiac outflow
or cardiac arrhythmias. In all of these 7 cases, and in
one additional case treated for SEGA (patient #12), rhab-
domyomas decreased in size under everolimus therapy
(Table 3). In one case (patient #13) cardiac arrhythmias
had been refractory to treatment with flecainide, meto-
prolol, amiodarone and metildigoxin. Initiation of evero-
limus therapy at 3 months of age led to rapid decrease of
associated rhabdomyoma size and therapeutic control of
cardiac arrhythmias within 1 month. Discontinuation of
treatment in the presence of stable disease at 4 months
of age however caused regrowth of the cardiac rhabdo-
myoma and recurrence of the arrhythmias warranting
restart of everolimus therapy with again rapid
normalization of the cardiac rhythm pattern. A second
attempt to withdraw everolimus during the second year
of life again led to recurrence of arrhythmias, barely
controllable under quadruple anti-arrhythmic therapy.
Addition of everolimus again alleviated disease severity.
Seven of 17 patients (41.2%) developed SEGA during
the observation period. In 6/7 patients everolimus was
started due to growing or symptomatic SEGA. In 5 of
these 6 patients (83.3%) SEGA size decreased signifi-
cantly during therapy, while in 1 patient (patient #8) no
effect was observed (Table 3, Fig. 4). Among the patients
treated for SEGA, 2 patients (patient #9 and #12) were
treated within the first month of life. A significant reduction
of SEGA size was documented on short time follow-up
MRI after 2 and 3months of treatment respectively.
Epilepsy and neurodevelopment under everolimus
therapy
Epilepsy was diagnosed in 14/17 patients (82.4%) during
their first 2 years of life. In 4/17 (23.5%) everolimus
treatment was started for treatment-resistant epilepsy
(Table 3). One patient (patient #5) showed marked
Fig. 1 Reasons for initiation of mTOR inhibitor treatment. CR cardiac
rhabdomyoma. SEGA subependymal giant cell astrocytoma.
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improvement and became almost free of seizures on
combination therapy with everolimus and oxcarbaze-
pine. The second patient (patient #10) was highly
refractory to anticonvulsants including levetiracetam,
oxcarbazepine, sultiame, vigabatrin, pregabalin, phey-
toin, pyridoxine and corticosteroids. He had epilepsy
surgery with removal of a cortical tuber and was
started on everolimus. However, despite a combin-
ation of vigabatrin, levetiracetam and everolimus, he
still suffers from daily seizures. Similarly, the third
patient (patient #17), experiencing refractory seizures
under levetiracetam, oxcarbazepine, vigabatrin,
ketogenic diet and everolimus, underwent epilepsy
surgery, which only led to short-term seizure free-
dom. The fourth patient (patient #16), by contrast,
previously experiencing refractory focal seizures
under levetiracetam, vigabatrin, phenobarbital and
ketogenic diet, showed 50% reduction of seizure fre-
quency after start of everolimus and was seizure free
under temporary toxic everolimus trough levels of
97.4 ng/ml. On reduction of everolimus to non-toxic
levels of 14-18 ng/ml seizures recurred. Finally the
patient underwent epilepsy surgery and is currently
free of seizures.
Table 2 Safety profile of mTOR inhibitor therapy
Patient
#
Age at start of
treatment
Dosages Comedications AE Vaccination status
before therapy
Vaccination status
during therapy
1 19months 2.5 mg
once daily
VGB, MAD Recurrent URTI / LRTI
Increase of cholesterol / TG
Complete NA
2 14months 2.5 mg 3
times per week
VGB, STM, VPA None Complete No live vaccines
3 15months 2.5 mg
once daily
LTG, VGB Transient stomatitis Complete NA
4 17months 2 mg
once daily
LEV, VPA Transient stomatitis Complete NA
5 12months 3 mg
once daily
OXC None NA No live vaccines
6 14 days 0.3 mg two
times per week
flecainide, propranolol None Incomplete NA
7 5months 1 mg daily ACTH, OXC, VGB, TMP Transient anemia No vaccinations NA
8 14months 2.5 mg daily different AEDs, TMP Recurrent URTI / LRTI
Increase of cholesterol / TG
Complete NA
9 7 days NA TPM, VGB, VPA,
propanolol, melatonin
Recurrent infections
Reduction of phosphate
Increase of cholinesterase
Increase of TG
Increase of LDH
NA Vaccinations under
therapy
10 2 months NA LEV, VGB, sotalol Recurrent infections NA Vaccinations during 3
months pause of therapy
11 7 days 0.05 mg every
other day
VPA, VGB, TPM,
propranolol, propafenone
Worsening of infantile
acne
Increase of phosphate
Increase of cholinesterase
NA Vaccinations under
therapy
12 1 month 0.03 mg/m2
twice per day
LEV, VGB Transient neutropenia
UTI
NA NA
13 3months 0.1 mg twice
per day
VGB, flecainide, metoprolol,
amiodarone, metildigoxin
Transient neutropenia
Recurrent URTI
NA NA
14 2 days 1.5-2 mg/m2
daily
VGB, LEV, digoxin, TMP/SMX,
nystatin
Increase of cholesterol / TG
Transient lymphopenia
NA No live vaccines
15 2 days 0.25 mg daily TMP/SMX, nystatin None NA No live vaccines
16 7 months 0.5 mg twice
per day
PB, VGB Recurrent infections NA No live vaccines
17 10months 5 mg daily OXC, VGB, KD None NA No live vaccines
ACTH adrenocorticotropic hormone, AE adverse event, CR cardiac rhabdomyoma, DD developmental delay, KD ketogenic diet, LDH lactate dehydrogenase, LEV
levetiracetam, LRTI lower respiratory tract infection, LTG lamotrigine, MAD modified Atkins diet, NA not available, OXC oxcarbazepine, PB phenobarbital, SEGA
subependymal giant cell astrocytoma, SEN subependymal nodule, SMX sulfamethoxazole, STM sulthiame, TG triglycerides, TMP trimethoprim, TPM topiramate, URTI
upper respiratory tract infection, UTI urinary tract infection, VGB vigabatrin, VPA valproic acid
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Seven of 17 patients (41.2%) developed IS during the
observation period (Table 4). IS occurred at a median
age of 5.5 months (range 1–7 months). Primary treat-
ments included ACTH (n = 1) or vigabatrin (n = 7). In 5
cases cessation of spasms occurred after a median dur-
ation of 3 months. No data were available for the
remaining 2 cases. Eight of 17 patients received everoli-
mus treatment within the neonatal period (first 3
months of life) prior to the vulnerable period for IS. The
remaining 9 patients were started on everolimus treat-
ment after 5 months of age. IS occurred in both groups.
Three of 8 patients (37.5%) in the neonatal group devel-
oped IS while 4/9 patients (44.4%) in the group of older
children were affected. Neurodevelopment was abnormal
in both groups on follow-up (Table 4).
Neurodevelopment prior to initiation of everolimus
treatment was evaluated in 14/17 children (Table 3).
Due to the lack of valid scoring systems in very young
children, developmental assessment was mostly car-
ried out by pediatricians and rated based on clinical
exam and the achievement of age-expected psycho-
motor milestones. While in 5 cases (35.7%) develop-
ment was reported as normal (patients #1, #6, #7, #12
and #15), 9 patients (64.3%) showed various degrees of
developmental delay. Reported findings included
delays in the acquisition of a social smile, delayed
achievement of speech or motor milestones (mostly
unsupported sitting) and the presence of muscular
hypotonia or focal neurologic deficits. On follow-up,
15 patients were tested (Table 3). Data on structural
assessments were available in 8 cases and included
Bayley II, K-ABC (Kaufman Assessment Battery for
Children), WPPSI-III (Wechsler Preschool and
Primary Scale of Intelligence), SON-R (Snijders-Oomen
non-verbal intelligence test), MFED (Münchener Funk-
tionelle Entwicklungsdiagnostik), VABS II (Vineland
Adaptive Behavior Scale), CBCL 1½-5 (Child Behavior
Checklist), ELFRA-2 (Elternfragebogen für die Früher-
kennung von Risikokindern) and GMDS (Griffith Men-
tal Developmental Scales) testing. Three patients
(20%) had normal results (patients #3, #6 and 10),
while 12 (80%) showed a wide spectrum of develop-
mental delay ranging from mild motor or speech delay
to global developmental delay. Interestingly, one pa-
tient (patient #2), reported with severe global develop-
mental delay on initial testing, showed significant
neurodevelopmental improvement after the start of
everolimus at the age of 14 months.
Fig. 2 Reported adverse events during everolimus treatment
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Discussion
We collected data from 17 TSC patients from 12 refer-
ring centers in Germany. All of these children received
everolimus therapy in the first 2 years of life. Treatment
was mainly initiated for symptomatic cardiac rhabdo-
myomas (35.3%), SEGA (29.4%) or the combination of
both (5.9%). Other reasons for mTOR inhibition were
refractory epilepsy (23.5%) and one rare case of congeni-
tal focal lymphedema of the leg (5.9%).
Safety profile
Everolimus was the only mTOR inhibitor used in our
study. Everolimus therapy was overall well tolerated
Table 3 Effect of mTOR inhibitor therapy on TSC-related manifestations and neurodevelopment
Patient # Reason for therapy Effect of therapy Development before
therapy
Development at follow-up
1 SEGA Decrease of SEGA Normal DD (not specified)
2 Congenital focal lymphedema Regression of congenital focal
lymphedema
DD (global) DD (not specified)
K-ABC, WPPSI-III
3 SEGA Decrease of SEGA DD (motor) Normal
SON-R
4 SEGA Decrease of SEGA DD (not specified) DD (global)
MFED
5 Epilepsy Decrease of seizure frequency DD (not specified) NA
6 CR Decrease of CR Normal Normal
7 CR Decrease of CR Normal DD (speech)
MFED
8 SEGA No effect DD (not specified) DD (global)
Bayley II
9 CR / SEGA Decrease of CR / SEGA NA DD (global)
10 Epilepsy Ongoing seizures NA Normal
11 CR / cardiac arrhythmia Decrease of CR NA DD (global)
12 SEGA Decrease of CR / SEGA Normal DD (global)
Bayley II
13 CR / cardiac arrhythmia Decrease of CR DD (motor) DD (motor)
Bayley II, VABS II,
CBCL 1½-5, ELFRA-2
14 CR Decrease of CR DD (global) DD (motor)
15 CR Decrease of CR Normal NA
16 Epilepsy Decrease of seizure frequency DD (not specified) DD (global)
Bayley II, GMDS
17 Epilepsy Ongoing seizures DD (motor) DD (not specified)
CBCL Child Behavior Checklist, CR cardiac rhabdomyoma, DD developmental delay, ELFRA Elternfragebogen für die Früherkennung von Risikokindern, GMDS
Griffith Mental Developmental Scales, K-ABC Kaufman Assessment Battery for Children, MFED Münchener Funktionelle Entwicklungsdiagnostik, NA not available,
SEGA subependymal giant cell astrocytoma, SON-R Snijders-Oomen non-verbal intelligence test, VABS Vineland Adaptive Behavior Scale, WPPSI Wechsler Preschool
and Primary Scale of Intelligence
Table 4 Effect of mTOR inhibitor therapy on IS and neurodevelopment
Patient
#
Age at start of
mTOR inhibitor
AAO of
IS
Previous
treatment
Time to cessation
of IS
Development prior to start
of mTOR inhibition
Development during
follow-up
1 19 months 7 months VGB 16 months Normal DD (not specified)
2 14 months 5 months VGB 3months DD (global) DD (not specified)
3 15 months 6 months VGB NA DD (motor) Normal
7 5 months NA ACTH, VGB 1month Normal DD (speech)
9 7 days 7 months VGB 4months NA DD (global)
11 7 days 1 month VGB NA NA DD (global)
12 1 day 5 months VGB 1month NA DD (global)
AAO age at onset, IS infantile spasms
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(Table 2). Grade 1–2 adverse events occurred in 70.6%
of patients and included dermatologic manifestations
(mild transient stomatitis, worsening of infantile acne),
subclinical laboratory changes (increase of cholesterol
and triglycerides, changes in phosphate levels, increase
of cholinesterase and lactate dehydrogenase, transient
anemia and neutropenia) as well as uncomplicated infec-
tions. During winter and under high everolimus trough
levels, one patient (patient #1) showed recurrent viral
respiratory tract infections, repeatedly complicated by
bacterial superinfection requiring antibiotic therapy. No
grade 3–4 adverse events were reported. Routine labora-
tory checks, in most cases monthly blood tests, proved
as helpful.
Treatment is currently ongoing in 76.5% and in the
remaining 23.5% was discontinued due to stable disease
with reduced SEGA volume in one case (patient #12),
reduction in cardiac rhabdomyoma size in one child
(patient #14 [13]), before epilepsy surgery in another pa-
tient (patient #16) and due to refractory seizures despite
treatment in the last patient (patient #17).
In most patients vaccinations with live-attenuated vac-
cines were not performed or in one case only in the con-
text of a treatment pause of 3 months (patients #10). In
2 cases vaccinations including live-attenuated vaccina-
tions were performed despite everolimus treatment and
without adverse events. No data regarding immune
response during vaccinations with everolimus were avail-
able. However, in the elder population everolimus treat-
ment has been previously reported as safe and helpful to
induce an immune response [15].
Dosing
Dosing regimens and absolute doses of everolimus var-
ied significantly and ranged from 0.05–0.3 mg daily in
neonates to 1–5 mg daily in children older than 5
months. No specific dosing recommendations for evero-
limus are available for neonates so far, however, previous
studies have shown that the primary elimination path-
way of everolimus, i.e. the CYP3A4 pathway, is ex-
tremely weak or absent in neonates, highlighting the
need for cautious use and repetitive drug monitoring
[16, 17]. Along these lines two patients in our study
showed toxic everolimus trough levels of around 100 ng/
ml after an initial dose of 0.4–0.45 mg (=1.5-2 mg/m2)
[13] and under a dose of 2 mg twice daily (=0,4 mg/kg)
(patient #16) respectively.
We searched the literature for reported cases of evero-
limus treatment in neonates (Table 5). All reported neo-
nates were treated for cardiac rhabdomyomas. The
median dose was 0.64mg/m2/day (range 0.12–1.0 mg/
m2/day), targeting median trough levels of 10.2 ng/ml
(range 4.5–13.7 ng/ml). This dose is significantly lower
than recommended doses in children above 3 years of
age (3.0 mg/m2/day) for SEGA treatment [18, 19].
Outcomes
Therapeutic benefits following everolimus treatment
were present in more than 80% of patients (Fig. 3) and
included decrease of cardiac rhabdomyoma size and
reduction of arrhythmias (8/8), decrease of SEGA size
(5/6), regression of congenital focal lymphedema (1/1)
and reduction of seizure frequency (2/4). Neither patient
#8, treated for SEGA, nor patients #10 and #17, treated
for highly refractory epilepsy, showed improvement
under everolimus.
Cardiac manifestations
Cardiac rhabdomyoma size rapidly decreased in all
patients treated with everolimus. Of special interest is
the case of patient #13. In this child discontinuation of
everolimus therapy after sustained reduction of a cardiac
rhabdomyoma repeatedly led to a regrowth and recur-
rence of potentially life-threatening arrhythmias war-
ranting restart of everolimus, again resulting in prompt
control of the arrhythmias that could not be achieved by
anti-arrhythmic medication alone. This observation
applies for beneficial effects of mTOR inhibition also on
the excitability of electrically active cardiomyocytes in
TSC-related arrhythmias comparable to its anticonvul-
sant effects in neurons. In 85.7% of patients treated for
cardiac rhabdomyomas, everolimus was started within
the first 3 months of life. These findings are in line with
several reports and small case series in the literature
similarly demonstrating relevant cardiac rhabdomyoma
size reduction in neonates with high-risk for cardiac sur-
gery, treated with everolimus [13, 20–31]. Our series
confirms that neonatal everolimus treatment is overall
well tolerated and beneficial for those infants even for
prolonged treatment.
Sega
SEGA size reduced significantly in the majority (83.3%)
of patients (Table 3). No patient required surgical re-
moval of SEGA during the study period. Two patients
with SEGA received everolimus in the neonatal period
(patients # 9 and #12) with beneficial effects on tumor
size (Fig. 4). Data on SEGA treatment in children below
2 years of age are still scarce. Kuki and colleagues suc-
cessfully used everolimus in 5 children under the age of
12 months and reported rapid SEGA volume reduction
of at least 50% in all treated patients within 6 months
[32]. Everolimus is currently widely used and approved
for the early treatment of SEGA. Our study provides fur-
ther evidence for the safety and beneficial effects of
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everolimus therapy for TSC-related SEGA under the age
of 2 years.
Other manifestations
One of our patients presented with congenital focal
lymphedema, a very rare presentation of TSC. The fre-
quency of congenital lymphedema in TSC patients has
been reported with 0.7% and only 11 patients have been
reported in the literature so far [33–40]. In our patient
everolimus treatment showed significant positive effects
on tumor texture and mobility of the affected limb (case
report under review).
Epilepsy
Epilepsy is a prevalent feature of TSC and the mTOR
pathway plays major roles in epileptogenesis [41]. Unlike
classical anticonvulsive drugs targeting ion channels,
synaptic receptors or modifying neurotransmitter release,
everolimus directly modifies downstream mechanisms
involved in TSC-related epileptogenesis. Thus, mTOR in-
hibition is a tempting approach for TSC-related refractory
Table 5 Summary of previous reports on mTOR inhibitor dosing in neonates
mTOR
inhibitor
AAO of
mTOR inhibitor
Dosing
regimen
Dose
[mg/m2/d]
Trough
levels [ng/ml]
Duration AE Prophylaxis Reference
EVE NA 0.25 mg
twice per day
2 days
per week
NA 5–15 2.5
months
Increase of TG
Self-limiting diarrhea
Decreased CD/CD8 ratio
lymphopenia
TMP/SMX (Demir et
al. 2012)
Sirolimus 10 days 0.4 mg daily NA NA 24 days Increase of TG TMP/SMX (Breathnach
et al. 2014)
EVE 20 days 0.1 mg daily 0.64 11 34 days Transient hypokalemia NA (Mohamed et
al. 2014)
EVE 2 days 0.25 mg twice
per day
2 days
per week
NA 3.6–7.8 3
months
NA NA (Dogan et
al. 2015)
EVE 4 days 0.1 mg daily 0.64 11.5 42 days NA NA (Goyer et
al. 2015)
EVE 9 days 0.1 mg daily 0.64 10.2 NA NA NA
EVE 21 days NA 3 4–5 NA Hyponatremia antibiotic
prophylaxis
(Mlczoch
et al. 2015)
EVE NA 0.25 mg twice
per day
2 days
per week
NA NA 4 weeks NA NA (Oztunc
et al. 2015)
EVE 2 days 0.15–0.2 mg
daily
1 10–15 19 days Toxic levels of 108 ng/ml under initial
dose of 0.4–0.45 mg (=1.5-2 mg/m2)
NA (Wagner
et al. 2015)
EVE 7 days 0.25 mg daily 1 NA 10
weeks
Mild mucositis
Increase of TG
NA (Colaneri
et al. 2016)
EVE NA 0.25 mg twice
per day
2 days
per week
NA 5–10 NA NA NA (Emir et
al. 2017)
EVE NA 0.5 mg daily NA NA NA NA NA (Hoshal et
al. 2016)
EVE 20 days 0.1 mg daily NA 13.7 34 days Suspected infection NA (Aw et
al. 2017)
EVE 4 days NA NA 11 42 days None NA
EVE 9 days 0.1 mg daily NA 10.2 NA Oral ulcers NA
EVE 1 day 0.1 mg daily NA 10.2 36 days None NA
EVE NA 0.03125
mg daily
0.12 3–7 2 weeks Adenovirus pneumonia
High trough levels of 20 ng/ml under
0.125 mg (0.0558mg/m2)
NA (Chang et
al. 2017)
EVE NA NA 0.35 1.81 NA NA NA
EVE NA 0.125
mg daily
0.51 NA Na NA NA
AAO age at onset, AE adverse events, EVE everolimus, NA not available, TG triglycerides, TMP/SMX trimethoprim/sulfamethoxazole
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epilepsy, underlined by the results of the EXIST-3 trial
that showed sustained reduction of seizure frequency
following adjunctive everolimus therapy in TSC-related
refractory epilepsy in patients above 2 years [5]. Our co-
hort is too small to draw definitive conclusions on the
benefits of everolimus treatment in TSC-related epilepsy
under 2 years of age. More than 80% of children in our
cohort developed seizures. Four were treated with everoli-
mus for refractory epilepsy. While two patients (patients
#10 and #17) are still suffering from daily seizures despite
the use of various antiepileptic regimens, including evero-
limus and epilepsy surgery, one patient is currently seizure
free under combination therapy with everolimus and
oxcarbazepine (patient #6). In the fourth patient (patient
#16) seizure frequency reduced to 50% under everolimus
therapy. Interestingly, trough levels within the toxic range
led to temporary seizure freedom, suggesting dose-
dependent efficacy of everolimus in this child. In our
cohort everolimus was effective as adjunctive antiepileptic
therapy in 2 of 4 children, corroborating the results of the
EXIST-3 trial [5]. Still, further studies are needed to inves-
tigate the benefits of mTOR inhibition on TSC-related
epilepsy in infancy and early childhood.
Neurodevelopment and infantile spasms
Neurodevelopment prior to initiation of everolimus
treatment was evaluated in 82.4% of children. While in
35.7% of these children development was reported as
normal, 64.3% showed psychomotor delay. On follow-
up, 88.2% of patients were evaluated. 20% of these had
normal results and 80% of patients showed circum-
scribed to global developmental delay. Interestingly, one
patient (patient #2) showed significant neurodevelop-
mental improvement after the start of everolimus at the
age of 14 months.
Neurodevelopmental outcome in TSC is closely linked
to IS [6, 7]. The literature on everolimus treatment in
TSC-related IS is scarce and only anecdotal reports exist
[10, 42]. Recently, Samueli and colleagues reported im-
proved neurocognitive outcome in 3 of 4 children with
TSC-related IS under everolimus treatment. The preva-
lence of IS in our cohort was 41.2%. Interestingly, IS
occurred in 37.5% of patients treated with everolimus
during the first 3 months of life, while 44.4% of patients
with everolimus initiation after 5 months of age devel-
oped IS (Table 4). Our patient cohort is currently too
small to draw solid conclusions about potential benefits
of early everolimus therapy on the occurrence of
TSC-related IS and on neurodevelopmental outcome.
Further studies are needed to evaluate the prophylactic
use of everolimus in the neonatal period regarding IS
and neurodevelopment.
Conclusions
We provide detailed evidence that everolimus treat-
ment is safe and efficacious in TSC patients under the
age of 2 years, mostly allowing improved long-term
outcome. The treatment was overall well tolerated and
adverse events were mild in the great majority of
cases. Benefits were reported in most cases including
reduction of cardiac rhabdomyomas, improvement of
cardiac arrhythmia, shrinkage of SEGA size, regression
of congenital focal lymphedema and reduction of
seizure frequency.
Fig. 3 Effects of everolimus treatment. CR cardiac rhabdomyoma. SEGA subependymal giant cell astrocytoma.
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Limitations of this study are a small cohort and the
still short follow-up period with a median follow-up of
2.1 years (range 0.5–5.5 years) since start of everolimus
treatment. Thus, no predictions on long-term safety
under maintenance therapy can be made. However, so
far no overt adverse events have been reported.
Further multicenter studies and registers with larger
cohorts and longer follow-up periods will determine the
long-term safety of early everolimus therapy in infancy
and early childhood and the effects on TSC-related
neurodevelopmental disorders.
Methods
To identify children with TSC and mTOR inhibitor
treatment, we contacted all TSC centers in Germany.
Seventeen patients from 12 different TSC clinics were
identified that fulfilled the inclusion criteria (patient with
a definitive diagnosis of TSC according to the 2012
International TSC Consensus Conference [12] and
treatment with an mTOR inhibitor started before 2 years
of age). Data were collected and rated by one primary
investigator per site. All patients and their parents or
legal guardians gave informed consent for individual
treatment with mTOR inhibitors and sharing of clinical
data.
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